Recombinant Anti-CD38 x Anti-CD59 Bispecific Antibody (Fab-IgG) is designed to be expressed as three chains, assembling in vivo and resulting in the construct of Fab-IgG (Tandem Fab-Fc). Fab-IgG has standard Fab and Fc domains, with no mutations, which may permit it has similar affinity binding and PK profile comparable to the parental antibodies. This BsAb can recruit complement to tumor cells. It is designed for the research of Multiple myeloma (MM); Hematologic malignancies therapy.
FuncS; Promising therapeutic agent
Multiple myeloma (MM); Hematologic malignancies
CD38; Cluster of differentiation 38; CD38 molecule; ADPRC1; ADPRC 1; Cyclic ADP ribose hydrolase
CD59; CD59 molecule, complement regulatory protein; 1F5; EJ16; EJ30; EL32; G344; MIN1; MIN2; MIN3; MIRL; HRF20; MACIF; MEM43; MIC11; MSK21; 16.3A5; HRF-20; MAC-IP; p18-20; CD59 glycoprotein; protectin; 1F5 antigen; MEM43 antigen; Ly-6-like protein; T cell-activating protein; human leukocyte antigen MIC11; lymphocytic antigen CD59/MEM43; 20 kDa homologous restriction factor; membrane inhibitor of reactive lysis; membrane attack complex inhibition factor; membrane attack complex (MAC) inhibition factor; surface anitgen recognized by monoclonal antibody 16.3A5; CD59 antigen p18-20 (antigen identified by monoclonal antibodies 16.3A5, EJ16, EJ30, EL32 and G344)
Our services and products are only for lab research, not for any diagnostic or therapeutic use.
Welcome! For price inquiries, we will get back to you as soon as possible.
To order, please email